MedTrace Logo

A Study of LY2484595 in Patients With High LDL-C or Low HDL-C

NCT01105975 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 398

Last updated 2018-03-22

Study results available
· View outcomes & findings →

Summary

The primary purpose of your participation in this study is to help answer the following research question(s)

* Whether LY2484595 in combination with a statin drug (atorvastatin, simvastatin or rosuvastatin; currently used to treat abnormal fat or cholesterol in blood) improves the blood fat profile more than statins alone.
* Whether LY2484595 alone improves blood fats profile compared to sugar pills.
* Whether LY2484595 interferes with break down or functioning of statins.
* Whether LY2484595 has any side effects that would not support testing it in future studies.

Conditions

Interventions

DRUG

LY2484595

Administered daily by mouth for 12 weeks

DRUG

Atorvastatin

Administered daily by mouth for 12 weeks

DRUG

Simvastatin

Administered daily by mouth for 12 weeks

DRUG

Rosuvastatin

Administered daily by mouth for 12 weeks

DRUG

Placebo for LY2484595

Administered daily by mouth for 12 weeks

DRUG

Placebo for Statins

Administered daily by mouth for 12 weeks

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • United States
  • Denmark
  • Germany
  • Netherlands
  • Poland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01105975 on ClinicalTrials.gov